Hadassah

Hadassah Researchers Investigate Link Between "Love Hormone" and Development of Autism

Thursday, Jan 24 2013

Researchers at the Hadassah Medical Center are investigating the connection between lower levels of the hormone, oxytocin, during pregnancy and the development of autism.

The study, led by Dr. David Mankuta, head of Labor and Delivery at Hadassah, in partnership with Prof. Nurit Yirmiya of the Hebrew University, will also examine the link between overexposure to oxytocin during birth and the development of autism.

Called the "love hormone," oxytocin has been found to be present at higher levels in couples who recently became romantically involved. The hormone has also been credited with playing a role in the bonding process between a mother and her newborn infant.

Dr. Mankuta explains: "There are drugs to prevent early contractions which are given routinely in some pregnancies that inhibit the effects of oxytocin. We will examine whether their use might be linked to the development of autism. In addition, we are examining whether the administration of oxytocin to induce labor might be harmful down the road and stimulate autism." It could be that administration of the hormone at this juncture may depress the body's natural secretion of oxytocin, thus increasing the newborn's risk of developing autism later on.

Studies have demonstrated that children with autism have lower levels of oxytocin in their blood—as little as half that of people without autism. One Hadassah study revealed a decline in the immunological components that operate the oxytocin system. Although autism is not diagnosed in children younger than two or three years old, there are anatomical markers that are more common in children who are later diagnosed with autism.

These include arched palate and a relatively large head circumference. In addition, certain risk factors for autism have been identified. To help parents who have children with autism to reduce the likelihood of having another child with the disease, Hadassah Hospital-Ein Kerem has opened a perinatology-oriented clinic. This is not a clinic for diagnosing autism or treating children who have autism; rather, parents of an autistic child who want more children come there for consultation. Dr. Mankuta believes that "with certain interventions, the risk for developing autism can be reduced for the future siblings of a child who has already been diagnosed with autism."

For example, autism is four times more prevalent in boys than in girls. Parents have the option to have a pre-implantation diagnosis and select female embryos only for implantation. Older fathers have a higher chance of having children with autism, so parents can be encouraged not to wait too long to have another child or to consider freezing the husband's sperm.

When the mother becomes pregnant, she can be given treatments such as progesterone to reduce the risk of preterm birth, steroids to accelerate development of the unborn baby's lungs, and aspirin to reduce the risk of preeclampsia—all factors that have been implicated in the development of autism. For a fuller story on autism and oxytocin, see Dan Even's January 2013 article in Ha'aretz, "The Love Hormone-Autism Connection."

For a fuller story on autism and oxytocin, see Dan Even's January 2013 article in Ha'aretz, "The Love Hormone-Autism Connection."

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Aug 16 2017

Gazan Boy Walks for First Time at Hadassah

Unable to stand on his feet, suffering from severe respiratory distress, a four-year-old boy from Gaza gained the ability to walk once Hadassah Hospital surgeons identified and removed a large tumor lodged in his chest.

READ MORE ›
alt_text

Wednesday, Aug 16 2017

Hadassah Hosts Health Innovation Conference

Over one hundred doctors, researchers, and entrepreneurs gathered at Hadassah Hospital Ein Kerem this summer to discuss how to advance the quality of patient care with computational power.

READ MORE ›
alt_text

Monday, Aug 14 2017

Hadassah Hosts First Human Trial with Drug to Fight Nasty Bacterial Infection

Immuron, an Australian biopharmaceutical company, has received approval from the Hadassah Medical Organization’s ethics committee and Israel’s Ministry of Health to begin its first clinical trial with a new drug to fight a bacterial infection called Clostridium Difficile (CDI).

READ MORE ›
alt_text

Thursday, Aug 3 2017

Mystery of Devastating Pediatric Disease Solved by Hadassah Team

A genetic mutation causing a rare and devastating pediatric neurological disease that has puzzled medical centers around the world has been identified at the Hadassah Medical Organization by Prof. Orly Elpeleg, head of Hadassah's Department of Genetics and Metabolic Diseases.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More